Biogen Inc.
Bear Case (25th pct.)
-39.9% vs price
Base Case (Median)
-19.4% vs price
Bull Case (75th pct.)
16.2% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-86.22 | -141.2% | High (40%) |
| PE Comparable | $125.74 | -39.9% | Medium (25%) |
| Graham Number | $125.78 | -39.9% | Medium (40%) |
| EV/EBITDA | $211.36 | 1.1% | Medium (20%) |
| EV/FCF | $404.73 | 93.5% | Medium (20%) |
| Earnings Power Value | $253.66 | 21.3% | Medium (50%) |
Based on 6 out of 8 methods, BIIB appears fairly valued at the current price of $209.15. The base case fair value of $168.57 implies 19.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.